Julian A. Symons - 27 Feb 2024 Form 4 Insider Report for Aligos Therapeutics, Inc. (ALGS)

Role
Executive Vice President, Chief Scientific Officer
Signature
/s/ Lesley Ann Calhoun, as attorney-in fact for Julian A. Symons
Issuer symbol
ALGS
Transactions as of
27 Feb 2024
Net transactions value
$0
Form type
4
Filing time
28 Feb 2024, 17:31:16 UTC
Previous filing
12 Sep 2023
Next filing
04 Mar 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALGS Stock Option (Right to Buy) Disposed to Issuer $0 -200,000 -100% $0.000000* 0 27 Feb 2024 Common Stock 200,000 $16.18 Direct F1
transaction ALGS Stock Option (Right to Buy) Disposed to Issuer $0 -105,000 -100% $0.000000* 0 27 Feb 2024 Common Stock 105,000 $3.06 Direct F2
transaction ALGS Stock Option (Right to Buy) Disposed to Issuer $0 -26,250 -100% $0.000000* 0 27 Feb 2024 Common Stock 26,250 $3.06 Direct F3
transaction ALGS Stock Option (Right to Buy) Award $0 +58,822 $0.000000 58,822 28 Feb 2024 Common Stock 58,822 $0.9600 Direct F1, F4
transaction ALGS Stock Option (Right to Buy) Award $0 +74,998 $0.000000 74,998 28 Feb 2024 Common Stock 74,998 $0.9600 Direct F2, F5
transaction ALGS Stock Option (Right to Buy) Award $0 +18,750 $0.000000 18,750 28 Feb 2024 Common Stock 18,750 $0.9600 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 200,000 of the issuer's shares granted to the reporting person on December 1, 2020. In exchange, on February 28, 2024, the reporting person received a replacement option, for 58,822 shares, having an exercise price of $0.96 per share.
F2 On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 105,000 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 74,998 shares, having an exercise price of $0.96 per share.
F3 On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 26,250 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 18,750 shares, having an exercise price of $0.96 per share.
F4 The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary.
F5 The shares subject to the option will vest and become exercisable as to 75% of the total number of shares subject to the option on the one year anniversary of the date of the grant and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the reporting person's continued service with the issuer on each such vesting date.

Remarks:

Executive Vice President, Chief Scientific Officer